- Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
- Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
- Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
- Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
- Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
- Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
- Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
More ▼
Key statistics
On Monday, Alpha Tau Medical Ltd (DRTS:NAQ) closed at 2.07, 18.29% above the 52 week low of 1.75 set on Jun 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.10 |
---|---|
High | 2.17 |
Low | 2.06 |
Bid | 2.06 |
Offer | 2.50 |
Previous close | 2.10 |
Average volume | 37.36k |
---|---|
Shares outstanding | 69.80m |
Free float | 51.88m |
P/E (TTM) | -- |
Market cap | 147.27m USD |
EPS (TTM) | -0.4165 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 20:59 BST.
More ▼